1778.3000 -16.10 (-0.90%)
NSE Mar 18, 2026 15:53 PM
Volume: 2.4M
 

1778.30
-0.90%
Phillip Capital
8 Given the +ve volume surprise in gGleevec and strong Taro performance, SUNP's Q4 earnings is 19% below our estimates. This implies weaker operating performance by SUNP'sbasebusinessandrelativelyweakerinventorypushingGleevec....
Sun Pharmaceutical I.. has an average target of 1940.86 from 7 brokers.
More from Sun Pharmaceutical Industries Ltd.
Recommended